Anzeige
Mehr »
Login
Dienstag, 21.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Aktienchance des Jahres! Ihre Chance auf explosive Gewinne!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 877757 | ISIN: FR0000051732 | Ticker-Symbol: AXI
Frankfurt
20.01.25
21:59 Uhr
0,002 Euro
+0,000
+14,29 %
1-Jahres-Chart
ATOS SE Chart 1 Jahr
5-Tage-Chart
ATOS SE 5-Tage-Chart
RealtimeGeldBriefZeit
0,0020,00320.01.
0,0020,00220.12.24
GlobeNewswire (Europe)
611 Leser
Artikel bewerten:
(2)

Atos International: Atos to evolve CNES's customizable flight software and maintain it for the next five years

Finanznachrichten News

Press Release

Atos to evolve CNES's customizable flight software and maintain it for the next five years

Paris, France - 16 December 2024 - Atos today announces it has been selected by The Centre National d'Etudes Spatiales to update and maintain its customizable flight software solution (LVCUGEN) for satellites and spacecraft. This new five-year contract reflects CNES's continued trust in Atos as a reliable technology partner.

Atos has partnered with CNES since 2019 on the development of LVCUGEN software components. This reusable customizable framework provides a solid foundation for embedded software development. LVCUGEN is based on software components, rigorous production processes and specific tools. Adaptable and modular, the solution can be customized by users according to their needs.

As the head development and maintenance partner for LVCUGEN, Atos ensures that the solution meets the requirements of CNES's current and future space programs and enables academic and industrial users to maximize the use of the technology and deploy its full potential in their projects.

By implementing a DevOps approach combined with open-source technologies, Atos promotes collaboration between space stakeholders to ensure the highest levels of quality while reducing costs and accelerating the development and production of embedded software based on the LVCUGEN software platform. Users benefit from an optimized environment and reduced validation times thanks to automation that complies with ECSS1 standards. This technical and organizational framework was developed by the European space community to guarantee the quality, safety and efficiency of projects carried out by all space stakeholders.

"Atos supports the smooth operation and evolution of our customizable embedded software development solution. The increasingly widespread adoption of this innovative architecture by our industrial, scientific and academic partners is a success for CNES and positions Atos as a key partner in our current and future major space programs," said Pierre-Baptiste Lambert, Head of the Flight Software Department, CNES.

"Thanks to our in-depth knowledge of the space field, our expertise in embedded software and our long-term commitment to CNES, Atos has perfectly met the challenges of reusability, reliability and cost optimization that are so critical in the development of spaceflight software," said Thomas Legras, Agency Director, Space Sector, Atos.

The LVCUGEN multi-target solution has been successfully deployed in the JUICE,N3SS, EyeSat, Angels, Kineis and SVOM space missions and the MMX Mars mission's IDEFIX rover, demonstrating its ability to meet the space industry's most ambitious challenges across multiple types of architectures, from traditional satellites to New Space nanosatellites.

***

About Atos

Atos is a global leader in digital transformation with c. 82,000 employees and annual revenue of c. € 10 billion. European number one in cybersecurity, cloud and high-performance computing, the Group provides tailored end-to-end solutions for all industries in 69 countries. A pioneer in decarbonization services and products, Atos is committed to a secure and decarbonized digital for its clients. Atos is a SE (Societas Europaea) and listed on Euronext Paris.

The purpose of Atosis to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space.

About CNES

Created in 1961, CNES is a programme agency, a technical centre and a space operator, bringing together all the functions that enable the French government to define and implement its space strategy, as well as to deploy public policies that require the support of the space sector (land management, agriculture, health, telecommunications, natural disasters, defence, etc.).

CNES ensures the availability of all the operational resources necessary for launches, positioning of spacecraft and space operations in orbit. CNES is an operator of vital importance (OIV), identified by the State as having activities essential to the survival of the nation. France, represented by CNES, is one of the main contributors to the European Space Agency (ESA).

To find out more about CNES, visit https://cnes.fr/en

Press contact

Isabelle Grangé - France | isabelle.grange@atos.net| +33 (0) 6 64 56 74 88


1 European Cooperation for Space Standardization

Attachment

  • Atos to evolve CNES customizable flight software and maintain it for the next five years (https://ml-eu.globenewswire.com/Resource/Download/8bfb3627-0345-4f0f-b330-501b45cea44b)

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.